Bradycardia Associated With Drug-Eluting Beads Loaded With Irinotecan (DEBIRI) Infusion for Colorectal Liver Metastases

被引:0
作者
Uei Pua
机构
[1] Tan Tock Seng Hospital,Department of Diagnostic Radiology
来源
CardioVascular and Interventional Radiology | 2013年 / 36卷
关键词
Irinotecan; Colorectal Liver Metastasis; Baseline Heart Rate; Sick Sinus Syndrome; Intravenous Atropine;
D O I
暂无
中图分类号
学科分类号
摘要
Intra-arterial injection of drug-eluting beads loaded with irinotecan (DEBIRI) is a new treatment option being investigated, with encouraging results, for unresectable colorectal liver metastases that are refractory to systemic chemotherapy (Martin et al., Ann Surg Oncol 18:192–198, 2011). Toxicity related to DEBIRI has also been described (Martin et al., Cardiovasc Intervent Radiol 33:960–966, 2010). Nevertheless, experience and literature related to DEBIRI remain limited, and experience with this treatment is expected to increase. The purpose of this article is to describe bradycardia occurring during DEBIRI administration, which has not been reported thus far.
引用
收藏
页码:864 / 866
页数:2
相关论文
共 21 条
[1]  
Martin RC(2011)Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study Ann Surg Oncol 18 192-198
[2]  
Joshi J(2010)Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry Cardiovasc Intervent Radiol 33 960-966
[3]  
Robbins K(2008)TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects Hepatogastroenterology 55 2077-2082
[4]  
Tomalty D(1998)Efficacy and toxicity of irinotecan in patients with colorectal cancer Semin Oncol 25 39-46
[5]  
Bosnjakovik P(1988)The mechanism of the inhibition of acetylcholinesterase by irinotecan (CPT-11)—a lead in explaining the cholinergic toxicity of CPT-11 and its time-course Proc Am Assoc Cancer Res 39 327-undefined
[6]  
Derner M(undefined)undefined undefined undefined undefined-undefined
[7]  
Martin RC(undefined)undefined undefined undefined undefined-undefined
[8]  
Howard J(undefined)undefined undefined undefined undefined-undefined
[9]  
Tomalty D(undefined)undefined undefined undefined undefined-undefined
[10]  
Robbins K(undefined)undefined undefined undefined undefined-undefined